相关实验视频

Updated: Feb 17, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

患有PD1-耐火性皮肤状细胞癌的患者的二线治疗方法:简要报告

Hisham AlSharif¹, Veronika Danchine¹, Kira Deekollu¹

¹Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.

|February 15, 2026

概括

对于晚期皮肤状细胞癌 (cSCC),该癌症在西米利马布治疗后进展,西米利马布显示33%的响应率与持久生存. 塞图西马布提供了反应,但在这种难以治疗的人群中,为了长期生存,通常需要进行救援手术.

科学领域:

在瘤学瘤学.
医学瘤学医学瘤学
免疫治疗是一种免疫疗法.

背景情况:

在治疗赛米普利马布后,晚期或转移性皮肤状细胞癌 (cSCC) 预后不佳.
对于耐火cSCC的二线治疗结果存在有限的数据.
对这种患者群体来说,研究非标签免疫疗法选择至关重要.

研究的目的:

描述非临床试验,针对晚期,复发性或耐火性cSCC的非标签免疫治疗方法.
评估伊皮利穆马布和塞图西马布作为二线疗法的疗效.
为了描述这些救援治疗后的患者结果.

主要方法:

一个综合性癌症中心的单一机构回顾案例系列.
对正在接受全身治疗的晚期cSCC患者的电子病历进行审查.
抽象患者人口统计,临床病理史,癌症数据,治疗方法和结果,包括反应率和存活率.

主要成果:

包括21名患者,其中13名患者接受 cetuximab,12名患者接受 ipilimumab 在先前治疗 (包括PD-1 抑制剂) 的进展后.
持久的完整反应仅在接受伊皮利姆巴治疗的患者中观察到.
在对二线治疗初始反应后,大多数幸存的患者需要进行救生手术.

结论:

在救援环境中,ipilimumab的响应率为33%,包括持久生存的完整响应.
在以前接受过塞米普利马布治疗的患者中,无论之前的反应如何,塞图西马布都诱导了反应.
大多数接受 cetuximab 治疗的患者经历了糟糕的生存结果,除非通过手术挽救.

关键词:

生物疗法是一种生物疗法.癌症的结局癌症的结果.皮肤状细胞癌瘤治疗免疫疗法免疫治疗

更多相关视频

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

相关概念视频

Skin Cancer

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...